Glaucoma surgery study
Protocol: STUDY00004680
Full Title
Outcomes Comparison between Baeveldt 350 and Ahmed ClearPath 250 tube shunts for the treatment of glaucoma
Description
This study enrolls people who need tube shunt implantation for the treatment of their severe glaucoma. The purpose of this study is to learn which type of tube shunt (a device used during the surgery) works the best.

This type of glaucoma surgery (tube shunt implantation) is designed to help the natural fluid inside the eye to drain out of the eye more easily. We don't know which tube shunt of these two (Baerveldt 350 or Ahmed ClearPath 250) is more effective in lowering pressure in the eye. Both tube shunts are FDA-approved and not experimental and are recognized as safe and effective glaucoma procedures, but there is no research that compares these two devices. We expect you will be in this research study for 2 years. The study is done as a part of your routine clinic visits after surgery and no extra visits are needed or anticipated. Study takes place at the Ross Eye Institute.

Technical Description

Comparison of two different tube shunts for the treatment of Glaucoma
Compensation: No
Eligibility
Adults ages 18+.
Have significant uncontrolled glaucoma despite medical, laser or previous surgery that requires tube shunt implantation.
Are scheduled for glaucoma tube shunt implantation surgery.
Age Group: Adults
Principal Investigator: Asher Weiner
Contact(s)
SHARON MICHALOVIC
sab1@buffalo.edu
+1 716-881-7975
Want to Learn More?
Enrollment Update

Due to COVID-19, new enrollment in research studies will be greatly limited. If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry. View the guidance for research participants for additional information.

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.